针对 COVID-19 的所谓干细胞治疗和外泌体疗法的商业营销：对直接面向消费者的在线广告声明的分析。
Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims.
机构信息
Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA; Sue and Bill Gross Stem Cell Research Center, University of California, Irvine, Irvine, CA, USA; Department of Family Medicine, University of California, Irvine, Irvine, CA, USA.
Program in Public Health, University of California, Irvine, 653 E. Peltason Drive, 2nd Floor, Irvine, CA 92697-3957, USA.
出版信息
Stem Cell Reports. 2023 Nov 14;18(11):2010-2015. doi: 10.1016/j.stemcr.2023.09.015. Epub 2023 Oct 26.
We identified 38 businesses advertising purported stem cell interventions and exosome products for COVID-19. These companies operated or facilitated access to 60 clinics. More than 75% of these clinics were based in the United States and Mexico. Thirty-six of the businesses marketed their stem cell and exosome products as treatments for Long COVID, six advertised them as "immune boosters," five claimed to treat patients in the acute infection phase, and two claimed their products were preventive. The least expensive product cost $2,950, the most expensive was $25,000, and the average listed cost for patients was $11,322. The promotion of these products is concerning because they have not been approved by national regulators and do not appear to be supported by convincing safety and efficacy data.
我们发现了 38 家宣传所谓干细胞干预和外泌体产品以治疗 COVID-19 的企业。这些公司经营或提供了 60 家诊所的服务。这些诊所中超过 75%位于美国和墨西哥。其中 36 家企业将其干细胞和外泌体产品作为治疗长新冠的方法进行营销，6 家宣传其为“免疫增强剂”，5 家声称可以治疗急性感染期的患者，2 家声称其产品具有预防作用。最便宜的产品售价为 2950 美元，最贵的为 25000 美元，患者的平均列出费用为 11322 美元。这些产品的推广令人担忧，因为它们尚未获得国家监管机构的批准，似乎也没有令人信服的安全性和疗效数据支持。
Zotero 插件